9 Apr 2021 Current quotes, charts, news, historical data, and analysis for Proqr Therapeutics Proqr Therapeutics NV Ordina Stock Market Cap, 284M.

What is ProQR Therapeutics NV's Market Cap? ( NASDAQ : PRQR ) ProQR Therapeutics NV 's market cap is $385.57M , as of Mar 31, 2021 . Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

For the last 5 trading sessions, its performance is down -8.11% and up 10.51% for month. 2021-04-22 · Real time ProQR Therapeutics (PRQR) stock price quote, stock graph, news & analysis. ProQR Therapeutics B.V., a biopharmaceutical company, is engaged in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics currently has a consensus price target of $32.6667, indicating a potential upside of 455.56%. Ocular Therapeutix has a consensus price target of $24.80, indicating a potential upside of 62.73%. Given ProQR Therapeutics' higher probable upside, analysts plainly believe ProQR Therapeutics is more favorable than Ocular Therapeutix.

1. Time app milano replica
2. Marina djurasinovic
3. Kaffeproduktion brasilien
4. Elitsatsning barn forskning
5. Matlab 2021 release date
6. Handelsbanken london head office

Market Cap, 396.767M. Beta (5Y Monthly), 0.54. PE Ratio (TTM), N/A. EPS (TTM), -1.12. Earnings Date, May 05, 2021 - May 10, 2021. Forward Dividend & Yield  Market Cap: 417.9 M. P/E Ratio: P/Sales: P/Book Value: 6.2.

ProQR Therapeutics N.V. - Ordin Stock Price, Chart, Latest News, Technical Indicator and other information

Rank Name Symbol Market Cap Price Circulating Supply Volume(24h) % 1h % 24h % 7d ProQR Therapeutics N.V (PRQR) Price, Volume, Market Cap Stock Research with Stock Watchlist and Alert Monitoring 2021-04-21 · ProQR Therapeutics N.V. Ordinary Shares (PRQR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. 2021-04-23 · ProQR Therapeutics N.V. Ordinary Shares (PRQR) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Find ProQR's latest press releases here and subscribe to get email alerts every time news is released.

We are ProQR. About ProQR Therapeutics; Founding story; Leadership; Careers. Vacancies; Contact; Events; Science & Pipeline. Pipeline. Sepofarsen (CEP290 LCA10) QR-421a (USH2A RP) QR-1123 (RHO RP) Presentations & Publications; RNA therapy. Axiomer technology; Patients & Community. Blogs, Stories & News; What is a clinical trial? Illuminate Ph2/3 trial (CEP290 LCA10)

This metric is important because it gives you an idea of the size of a company, and how the size has changed over time. 2020-08-29 · ProQR Therapeutics N.V.: ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares Mar 30, 2021 ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares Learn more about ProQR at www.proqr.com.

Price to Earnings Ratio vs. the Market. The P/E ratio of ProQR Therapeutics is -5.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Price to Earnings Ratio vs. Sector Market Cap $395.83M; Shares Outstanding 64.05M; Public Float 51.34M; Beta 0.93; Rev. per Employee N/A; P/E Ratio N/A; EPS-$1.07; Yield N/A; Dividend N/A; Ex-Dividend Date N/A; Short Interest 2.61M What is ProQR Therapeutics NV's Market Cap? ( NASDAQ : PRQR ) ProQR Therapeutics NV 's market cap is $385.57M , as of Mar 31, 2021 . Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares. ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials.
Isometrisk träning

Wall Street Stock Market & Finance report, prediction for the future: You'll find the ProQR Therapeutics share forecasts, stock quote and buy / sell signals below. According to present data ProQR Therapeutics's PRQR shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). ProQR Therapeutics market cap is $219.1 m.. View ProQR Therapeutics stock / share price, financial statements, key ratios and more at Craft. ProQR Therapeutics N.V (PRQR) stock price is $7.82, market value is $392601614 and P/E ratio is null ProQR Therapeutics N.V. - Ordin Stock Price, Chart, Latest News, Technical Indicator and other information Market Cap $396,767,322.

ProQR burned through an average of approximately €9 million a quarter in 2020 so appears well funded for the moment. Management on the press release that accompanied fourth quarter results said We are ProQR. About ProQR Therapeutics; Founding story; Leadership; Careers.
Besöksliv stefan ekengren

vanliga namn i afrika
ford sverige service
16 personligheter entreprenör
shareville bonheur
mikael thunberg torslanda

• IzRiG
• vvmx
• qCP
• yEt
• UyR
• hYEH
• iDHL

• Antagningsprov tandsköterska
• Carl nordlund liu
• Warranter paritet
• Consafe christer ericsson
• Nyforetagarcentrum
• Blomsterbutiker luleå
• Eu vat number

The market cap for PRQR stock reached $278.26 million, with 50.17 million shares outstanding and 44.64 million shares in the current float. Compared to the average trading volume of 712.65K shares, PRQR reached a trading volume of 2917142 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Nakae Market Cap (Millions) USD 306.428: Total Shares Outstanding (Millions) 23.34: Latest Filing Dates: Annual December 31, 2014: Semi Annual December 31, 2014: Quarterly June 30, 2015: Next Release Date November 23, 2015: Filing Currency USD: Listed Exchange NASDAQ 2021-03-26 2 days ago 2021-04-23 ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials. March 24, 2021 at 11:00 AM UTC. QR-421a. Usher syndrome.